Outcomes of Autologous Stem Cell Transplant (ASCT) in Patients with t (11;14) Multiple Myeloma(MM)

MM is a clonal disorder of malignant plasma cells. Standard of care for newly diagnosed MM is induction with triplet regimen chemotherapy followed by ASCT. Patients are stratified based on cytogenetic analysis as being high risk and standard risk. t(11;14) comprises ∼ 15-20% of newly diagnosed MM, making it the most common translocation. t(11;14) has been classified as standard risk. However, it is now increasingly being considered as intermediate risk, conferring inferior outcome compared with standard-risk MM.(Walker, Wardell et al.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 358 Source Type: research